Novo Nordisk on Tuesday said it expects sales and profits to decline this year, as the maker of Wegovy faces growing competition in the obesity market.
The Danish pharma giant said it expects sales to decrease in the range of 5% to 13% in 2026, more than the 3% decrease forecasted by analysts surveyed by Visible Alpha. Novo also expects operating profits to decrease in the range of 5% to 13%, while analysts predicted a 5% decrease.
STAT Plus: With the Wegovy pill, Novo Nordisk undercuts Eli Lilly in direct-to-consumer market
Shares of Novo plummeted more than 14% as of midday Tuesday. The company was scheduled to report earnings on Wednesday but released these results early.
STAT+ Exclusive Story
Already have an account? Log in
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.
Already have an account? Log in
Individual plans
Group plans
To read the rest of this story subscribe to STAT+.